0013158 2022 RIV US eng J
Válková, Veronika^G - Vydra, Jan - Marková, Markéta - Cerovská, Ela - Vraná, Milena - Marinov, Iuri - Čechová, Hana - Cetkovský, Petr - Vítek, Antonín - Šálek, Cyril
WT1 gene expression in peripheral blood before and after allogeneic stem cell transplantation is a clinically relevant prognostic marker in AML: a single-center 14-year experience.
Clinical lymphoma myeloma & leukemia. Vol. 21, no. 2 (2021), s. e145-e151. ISSN 2152-2650
Institucionální podpora: RVO:00023736
Klíčová slova: allogeneic * AML * MRD monitoring * prognostic factors * WT-1
Cite Score: 3.600, rok: 2021; SJR: 0.778, rok: 2021; IF: 2.822, rok: 2021
DOI: 10.1016/j.clml.2020.09.008

Anotace: Recent years have shown that minimal or measurable residual disease (MRD) is one of the most important independent prognostic factors in acute myeloid leukemia (AML), and its monitoring is crucial in treatment planning and risk stratification. The basis of such stratification is the identification and monitoring of a specific MRD marker in individual patients. Wilms’ tumor gene 1 (WT1) encodes a transcription factor that is overexpressed in several hematologic malignancies, including AML in up to 80% to 90% of cases. Thus, it is not a marker specific for AML, but rather reflects abnormal myelopoiesis. In this work, we summarized our experience with WT1 monitoring before allo-HSCT, but also the usefulness of this marker in long-term follow-up after allo-HSCT.